# Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) (RFA-CA-27-001)

**Plain-English Eligibility Score:** 78/100

| Field | Value |
|---|---|
| Opportunity number | RFA-CA-27-001 |
| Title | Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) |
| Agency | National Institutes of Health |
| Status | posted |
| Posted / open date | 2026-06-03 |
| Close date | 2026-11-10 |
| Award ceiling | $150,000 |
| Award floor | n/a |
| Estimated total funding | $5,100,000 |
| Funding category | Health |
| Eligible applicants | County governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); State governments; Public housing authorities/Indian housing authorities; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Special district governments; Small businesses; Native American tribal governments (Federally recognized); Private institutions of higher education |
| Eligibility notes | Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
| CFDA / Assistance listing | 93.394 |
| Summary | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant  |
| Agency contact | Kelly.crotty@nih.gov |

## Why this score
- Small businesses are listed as eligible applicants.
- Nonprofits are listed as eligible applicants.
- Only 6 days until the deadline.
- Award ceiling of $150,000 suits small organizations.

Source: Grants.gov (U.S. Department of Health and Human Services) (https://www.grants.gov/search-results-detail/360536). Last refreshed: 2026-11-03T18:08:06.385Z.
Data from Grants.gov. Always read the full notice of funding opportunity before applying. Informational only; not legal or grant-writing advice.